The Health Resources and Services Administration today released a proposed rule that would implement an Affordable Care Act provision requiring a binding administrative dispute resolution process for 340B Drug Pricing Program participants who claim they have been overcharged for drugs purchased through the program. Under the proposed process, which also would be available to drug manufacturers, a decision-making body within the Department of Health and Human Services would review and resolve the claims. The proposed rule will be published in the Aug. 12 Federal Register with comments accepted through Oct. 11. AHA staff are reviewing the rule, and member hospitals that are 340B participants will receive more information.

Related News Articles

Headline
The AHA Jan. 9 urged the Medicare Payment Advisory Commission to consider, during its next meeting Jan. 15-16, higher payment updates for the…
Headline
The 1st U.S. Circuit Court of Appeals Jan. 7 denied the government’s motion for a stay in a lawsuit filed by the AHA, the Maine Hospital Association and four…
Headline
The application period has opened for hospitals to apply for the latest allocation of Medicare-funded graduate medical education residency slots under Section…
Headline
The Centers for Medicare & Medicaid Services has implemented an online form for providers to submit complaints regarding Medicare Advantage plans. A CMS…
Headline
The Centers for Medicare & Medicaid Services released a memo Dec. 16 announcing the agency’s intent to conduct a voluntary pilot in 2026, called the…
Headline
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program.  “When…